Highlight
- The Phase 3 CIFFREO trial failed to meet its primary efficacy endpoint, showing no significant difference in North Star Ambulatory Assessment (NSAA) scores between fordadistrogene movaparvovec and placebo at 52 weeks.
- Safety data revealed a higher incidence of adverse events and serious adverse events in the gene therapy group, including significant gastrointestinal and hepatic complications.
- Based on the unfavorable benefit-risk profile, Pfizer has discontinued all further clinical development of fordadistrogene movaparvovec for Duchenne muscular dystrophy (DMD).
Background: The Challenge of Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) remains one of the most challenging X-linked recessive neuromuscular disorders, primarily affecting young males. Caused by mutations in the DMD gene, the condition results in a total or near-total absence of dystrophin, a critical protein that maintains the structural integrity of muscle fibers. This absence leads to progressive muscle degeneration, loss of ambulation in the second decade of life, and eventual respiratory or cardiac failure.
The therapeutic landscape for DMD has shifted dramatically in recent years toward genetic interventions. Since the DMD gene is too large for standard viral vector delivery, researchers developed “mini-dystrophin” transgenes—truncated but functional versions of the protein. Fordadistrogene movaparvovec was designed as an investigational recombinant adeno-associated virus 9 (rAAV9)-based vector carrying such a transgene. While early-phase data suggested potential, the definitive Phase 3 CIFFREO trial was designed to provide the rigorous evidence required for global regulatory approval.
Study Design and Methodology
CIFFREO was a global, multicenter, Phase 3, double-blind, randomized, placebo-controlled study conducted across 45 sites in 15 countries. The study enrolled 122 male ambulatory participants aged 4 to less than 8 years with a confirmed genetic diagnosis of DMD. Participants were required to be on a stable daily dose of glucocorticoids.
The participants were randomized 2:1 into two cohorts:
- Cohort 1: Received a single intravenous infusion of fordadistrogene movaparvovec (2 × 10^14 vector genomes [vg]/kg) on day 1 and a placebo on day 390.
- Cohort 2: Received a placebo on day 1 and the active gene therapy on day 390 (cross-over design).
The primary efficacy endpoint was the change from baseline to week 52 in the North Star Ambulatory Assessment (NSAA) total score. The NSAA is a 17-item validated scale used to measure functional motor abilities in ambulatory children with DMD. Secondary endpoints included the 10-meter run/walk time and the time to rise from the floor.
Key Findings: Efficacy and Safety Results
Efficacy Outcomes
The primary analysis included 64 participants in the fordadistrogene movaparvovec group and 28 in the placebo group who completed the 1-year follow-up. At baseline, the mean NSAA scores were comparable (22.5 in the treatment group vs. 23.5 in the placebo group).
At the 52-week mark, the least squares mean change from baseline in the NSAA total score was 1.46 (SE 0.43) for the fordadistrogene movaparvovec group compared to 1.37 (SE 0.65) for the placebo group. The difference between the groups was a mere 0.09 points (95% CI -1.46 to 1.64; p=0.91), which was not statistically significant. Essentially, the gene therapy failed to demonstrate any functional advantage over the natural progression of the disease under standard corticosteroid care during the first year of treatment.
Safety Profile
Safety was a significant concern throughout the trial. Adverse events (AEs) were nearly universal in the treatment group, occurring in 78 of 79 participants (99%), compared to 27 of 35 (77%) in the placebo group. The most frequent AEs associated with the gene therapy included:
- Vomiting (76% vs. 14% in placebo)
- Pyrexia (62% vs. 9% in placebo)
- Decreased appetite (33% vs. 3% in placebo)
- Nausea (29% vs. 9% in placebo)
- Elevated liver enzymes (glutamate dehydrogenase) (24% vs. 0% in placebo)
Serious adverse events (SAEs) were also more prevalent in the treatment arm (32% vs. 14%). While no deaths occurred during the study period, the high rate of systemic inflammatory responses and hepatic stress contributed to the overall negative assessment of the therapy’s safety profile.
Expert Commentary and Clinical Interpretation
The failure of the CIFFREO trial is a sobering moment for the DMD community and the field of gene therapy. Several factors may explain why fordadistrogene movaparvovec failed to achieve the desired clinical impact despite promising preclinical data.
One primary consideration is the design of the mini-dystrophin transgene itself. Different gene therapy candidates (such as Sarepta’s delandistrogene moxeparvovec) utilize different promoters and protein domains. It is possible that the specific construct used in fordadistrogene movaparvovec did not provide sufficient functional stability or localization at the sarcolemma to translate into gross motor improvements. Furthermore, the high dose of rAAV9 (2 × 10^14 vg/kg) may have hit a ceiling where the metabolic and immunological burden on the child outweighed the cellular benefits of the transgene expression.
The results also highlight the “placebo effect” or the impact of high-quality standard care in clinical trials. The placebo group showed a slight improvement in NSAA scores (1.37 points), which may be attributed to the rigorous corticosteroid regimens and physical therapy associated with clinical trial participation. This makes the threshold for demonstrating superiority for any new DMD therapy exceptionally high.
Clinicians must now pivot toward other emerging therapies. While this specific agent has been discontinued, the lessons learned regarding AAV9 dosing and the necessity of robust primary endpoints in DMD trials will inform future research. The disappointment of CIFFREO underscores that surrogate biomarkers (like micro-dystrophin expression levels) do not always predict clinical functional benefit.
Conclusion
The Phase 3 CIFFREO study provides definitive evidence that fordadistrogene movaparvovec, at the dose and formulation tested, does not offer a significant functional benefit for ambulatory boys with Duchenne muscular dystrophy. Given the lack of efficacy and the high incidence of serious adverse events, the benefit-risk profile is firmly negative. Pfizer’s decision to discontinue the program reflects a commitment to patient safety and evidence-based medicine. The focus of the scientific community now returns to refining gene delivery mechanisms and exploring combination therapies to address this devastating disease.
Funding and Trial Information
This study was funded by Pfizer. ClinicalTrials.gov Identifier: NCT04281485.
References
- Muntoni F, Nascimento A, Shin J, et al. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. The Lancet Neurology. 2026;25(3):245-255.
- Goemans N, et al. The North Star Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Journal of Neuromuscular Diseases. 2020;7(1):1-11.
- Wang Z, et al. Muscle-targeted gene therapy for Duchenne muscular dystrophy: challenges and opportunities. Molecular Therapy. 2022;30(4):1350-1365.
